LCA reports for Johnson & Johnson Innovative Medicine sponsored phase-2, 3, 4 clinical trials

Objective: To calculate the global warming potential, in carbon dioxide
(CO2) equivalent emissions, from all in-scope activities involved in
phase-1, 2, 3, and 4 clinical studies spanning multiple disease areas
Design: Retrospective analysis Data source:  Data collected by
Johnson & Johnson Innovative Medicine during study conduct Studies
included:  Johnson & Johnson Innovative Medicine
sponsored 77242113PSO2001 (ClinicalTrials.gov: NCT05364554),
42756493BLC2002 (ClinicalTrials.gov: NCT03473743), 54767414MMY3012
(ClinicalTrials.gov: NCT03277105), VAC18193RSV3006 (ClinicalTrials.gov:
NCT05070546), R092670PSY3016 (ClinicalTrials.gov: NCT04072575), and
28431754DIA4032 (ClinicalTrials.gov: NCT04288778) clinical studies
conducted between 2018-2023 Main outcome: measure CO2 equivalents (CO2e)
for in-scope clinical trial activities calculated according to
Intergovernmental Panel on Climate Change (IPCC) 2021 impact assessment
methodology.

研究目标：计算覆盖多疾病领域的1期、2期、3期及4期临床试验中纳入范围内全部活动的全球变暖潜能值（global warming potential），以二氧化碳（carbon dioxide, CO₂）当量排放量为计量标准。
研究设计：回顾性分析。
数据来源：数据由强生创新制药（Johnson & Johnson Innovative Medicine）在临床试验实施期间采集。
纳入研究：纳入强生创新制药赞助的2018年至2023年间开展的6项临床试验，具体包括：77242113PSO2001（ClinicalTrials.gov编号：NCT05364554）、42756493BLC2002（ClinicalTrials.gov编号：NCT03473743）、54767414MMY3012（ClinicalTrials.gov编号：NCT03277105）、VAC18193RSV3006（ClinicalTrials.gov编号：NCT05070546）、R092670PSY3016（ClinicalTrials.gov编号：NCT04072575）及28431754DIA4032（ClinicalTrials.gov编号：NCT04288778）。
主要结局指标：依据政府间气候变化专门委员会（Intergovernmental Panel on Climate Change，IPCC）2021年影响评估方法学，计算纳入范围内临床试验活动的二氧化碳当量（CO₂e）。